Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Scorpius Holdings Inc NHWK


Primary Symbol: SCPX

Healthcare Biotechnology
Scorpius Holdings, Inc., formerly NightHawk Biosciences, Inc., is an integrated contract development and manufacturing company. The Company is focused on advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. Its analytical services include development of a comprehensive range of analytical test methods to characterize complex biologics, including cell therapy-based products, protein therapeutics, vaccines and advanced therapies. Its Clinical Biomanufacturing includes cGMP Mammalian Cell Culture, and cGMP Microbial Fermentation. Its San Antonio facility is focused on the commercial-scale manufacturing of biodefense-focused molecules and biologics therapeutics. Its biomanufacturing services focus on accelerating product development timelines from pre-clinical evaluation to first-in-human studies.


NYSEAM:SCPX - Post by User

Scorpius Holdings Inc
<< Previous
 Bullboard Posts
User Avatar Image
(13)
•••
Post by ghayeson Nov 08, 2021 3:06pm
343 Views
Post# 34101464

anyone else following HTBX ?

anyone else following HTBX ?Anyone else got any insights into HTBX ? had a couple of run ups a year ago and 6 months ago, since then, it is just dithering around the low $5 range. I  look at their most advanced product pipleline item, HS110 a treatment for non-small cell lung cancer - and I see that the study isn't due to be completed until August 2022.A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov 
That is a while to wait.
Anyone give me some other reasons to get in at $5 now?
Otherwise I just see this drifting down to.. $5, $3, $2...?
Seems to be a good complany with some good products, but when are they going to deliver a breakthrough?  GLTA...
<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities